Serotherapy |
Campath |
Campath |
ATG/Campath: 86% |
ATG 67%; Campath
33% |
ATG/thymoglobulin 33%; Campath 67% |
Alkylating agent
|
RICf (melphalan)
|
RIC (Melphalan)
|
MAC f (busulfan/Treosulfan) 90%;
RIC (Melphalan) 10%
|
MAC(Busulfan/CPM) 42%;
RTC(Treosulfan/CPM) 25%;
RIC(Melphalan) 33%
|
Treosulfan/Thiotepa 75%;
Melphalan/Thiotepa 27%
|
Stem cell source b
|
BM 96%; PBSC 4% |
BM |
Cord |
BM 69%; PBSC 14%; Cord 17% |
BM 66%; PBSC 32%; Cord
2% |
Donor c
|
Matched 75%; mismatch 25%. Sibling 24%; Unrelated 76%
|
MRD 21%; MUD 47%;
MMUD 32%
|
HLA-Match 6/6:30%
HLA-Mis 5/6: 48%
HLA-Mis ≤4/6: 22%
|
MRD 25%; MMRD 8%; MUD 50%; MMUD 17%
|
MRD 17%; MUD 37%;
MMRD 10%; MURD 37%
|
2nd cell therapy d
|
19% |
35% |
― |
RTC 0%; MAC 13%; RIC 67% |
32 % |
EFS e
|
― g
|
― |
6 yr:
34~69% |
2 yr: RTC 89%; MAC 73%; RIC 42% |
― |
OS
|
1 yr: 80~91%
5 yr: 80~82%
|
1 yr: 82%; 18-month: 68%
|
6 yr: 55%
|
2 yr: RTC 89%; MAC 73%; RIC 83%
|
5 yr: 75%
|